Cutia Therapeutics (CUTIA-B) has unveiled a voluntary on-market share repurchase programme covering the period from 2 October 2026 to 31 December 2026. The initiative will be executed under the general mandate approved at the 26 June 2026 annual general meeting.

Key parameters: • Funding cap: up to RMB30.00 million (approximately HK$34.90 million), representing a potential maximum of 36.34 million shares based on prevailing market prices. • Pricing discipline: each repurchase price will not exceed 5% above the average closing price of the shares over the five trading days immediately preceding the transaction, in line with Hong Kong Listing Rules. • Financing: transactions will be funded by existing cash flow and internal resources, with the Board emphasising that working-capital and gearing levels will not be materially affected. • Duration: three months, ending 31 December 2026, with execution subject to market conditions and Board discretion.

Management stated that the buy-back is intended to signal confidence in the company’s long-term prospects and enhance shareholder value, while clarifying that the full mandate may not necessarily be utilised.

Cutia Therapeutics is an R&D-driven, dermatology-focused biopharmaceutical company backed by 6 Dimensions Entities and 6 Dimensions Capital. Shareholders and potential investors are advised to exercise caution when trading the company’s shares.